A B Pardee|K Keyomarsi - JoVE Visualize

Showing results (121-130 of 222) with videos related to

Pageof 23

Sort By:

Oncogene|December 29, 2000

Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sitesL Huang, Y Sowa, T Sakai, et al.

Biotechniques|November 21, 2000

Detection of the level of estrogen receptor and functional variants in human breast cancers by novel assaysD K Biswas, A P Cruz, A B Pardee

Mutation Research|February 1, 1984

Comparative analysis of caffeine and 3-aminobenzamide as DNA repair inhibitors in Syrian baby hamster kidney cellsS K Das, C C Lau, A B Pardee

Cancer Research|October 23, 1997

Re-expression of elafin in 21MT2 breast carcinomas by phorbol 12-myristate 13-acetate is mediated by the Ap1 site in the elafin promoterM Zhang, D Magit, A B Pardee, et al.

Cancer Research|February 1, 1989

Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase ID A Boothman, D K Trask, A B Pardee

Proceedings of the National Academy of Sciences of the United States of America|December 1, 1987

Cell-cycle-specific interaction of nuclear DNA-binding proteins with a CCAAT sequence from the human thymidine kinase geneG B Knight, J M Gudas, A B Pardee

Proceedings of the National Academy of Sciences of the United States of America|August 1, 1979

Loss of epidermal growth factor requirement and malignant transformationP V Cherington, B L Smith, A B Pardee

Oncogene|November 12, 1998

Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53S Rao, M Lowe, T W Herliczek, et al.

Oncogene|September 7, 1995

Deregulation of cyclin E in breast cancerK Keyomarsi, D Conte, W Toyofuku, et al.

The Journal of Biological Chemistry|October 5, 1992

Cloning and characterization of human cyclin D3, a cDNA closely related in sequence to the PRAD1/cyclin D1 proto-oncogeneT Motokura, K Keyomarsi, H M Kronenberg, et al.

Pageof 23

Showing results (121-130 of 222) with videos related to

Sort By:

Pageof 23

Oncogene|December 29, 2000

Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sitesL Huang, Y Sowa, T Sakai, et al.

Biotechniques|November 21, 2000

Detection of the level of estrogen receptor and functional variants in human breast cancers by novel assaysD K Biswas, A P Cruz, A B Pardee

Mutation Research|February 1, 1984

Comparative analysis of caffeine and 3-aminobenzamide as DNA repair inhibitors in Syrian baby hamster kidney cellsS K Das, C C Lau, A B Pardee

Cancer Research|October 23, 1997

Re-expression of elafin in 21MT2 breast carcinomas by phorbol 12-myristate 13-acetate is mediated by the Ap1 site in the elafin promoterM Zhang, D Magit, A B Pardee, et al.

Cancer Research|February 1, 1989

Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase ID A Boothman, D K Trask, A B Pardee

Proceedings of the National Academy of Sciences of the United States of America|December 1, 1987

Cell-cycle-specific interaction of nuclear DNA-binding proteins with a CCAAT sequence from the human thymidine kinase geneG B Knight, J M Gudas, A B Pardee

Proceedings of the National Academy of Sciences of the United States of America|August 1, 1979

Loss of epidermal growth factor requirement and malignant transformationP V Cherington, B L Smith, A B Pardee

Oncogene|November 12, 1998

Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53S Rao, M Lowe, T W Herliczek, et al.

Oncogene|September 7, 1995

Deregulation of cyclin E in breast cancerK Keyomarsi, D Conte, W Toyofuku, et al.

The Journal of Biological Chemistry|October 5, 1992

Cloning and characterization of human cyclin D3, a cDNA closely related in sequence to the PRAD1/cyclin D1 proto-oncogeneT Motokura, K Keyomarsi, H M Kronenberg, et al.

Pageof 23